2型糖尿病合并脂肪肝患者应用二甲双胍与阿托伐他汀钙联合治疗的效果分析

Effect of Metformin Combined with Atorvastatin Calcium in Patients with Type 2 Diabetes Mellitus Complicated with Fatty Liver

目的:探讨2型糖尿病(T2DM)合并脂肪肝患者应用二甲双胍与阿托伐他汀钙联合治疗的效果。方法:选择2021年1月-2022年6月新干县中医医院收治的80例T2DM合并脂肪肝患者为研究对象,按照随机数字表法将患者分为二甲双胍组与联合治疗组,每组40例。二甲双胍组采用二甲双胍治疗,联合治疗组采用二甲双胍联合阿托伐他汀钙治疗。比较两组的临床疗效、糖脂代谢指标、血管内皮功能及预后情况。结果:联合治疗组治疗总有效率为95.00%,高于二甲双胍组的80.00%,差异有统计学意义(P<0.05)。治疗后,两组胰岛素抵抗指数、甘油三酯、总胆固醇均低于治疗前,且联合治疗组均低于二甲双胍组,差异均有统计学意义(P<0.05);两组内皮素均低于治疗前,一氧化氮均高于治疗前,且联合治疗组内皮素低于二甲双胍组,一氧化氮高于二甲双胍组,差异均有统计学意义(P<0.05)。联合治疗组预后不良发生率为1.67%,低于二甲双胍组的15.00%,差异有统计学意义(P<0.05)。结论:二甲双胍联合阿托伐他汀钙治疗对T2DM合并脂肪肝患者疗效明显,且能有效改善患者糖脂代谢及血管内皮功能,且安全性良好。

Objective:To investigate the effect of Metformin combined with Atorvastatin Calcium in type 2 diabetes mellitus(T2DM)patients with fatty liver.Methods:A total of 80 T2DM with fatty liver disease patients admitted to Xingan Hospital of Traditional Chinese Medicine from January 2021 to June 2022 were selected as the study objects,and the patients were divided into a Metformin group and a combined treatment group according to random number table method,with 40 cases in each group.The Metformin group was treated with Metformin,and the combined treatment group was treated with Metformin and Atorvastatin Calcium.The clinical efficacy,glucose and lipid metabolism indexes,vascular endothelial function and conditions of prognosis were compared between the two groups.Results:The total effective rate of combined treatment group was 95.00%,which was higher than 80.00%of the Metformin group,the difference was statistically significant(P<0.05).After treatment,insulin resistance index,triglyceride and total cholesterol in 2 groups were lower than before treatment,the combined treatment group was lower than the Metformin group,the differences were statistically significant(P<0.05);the endothelin in both groups was lower than before treatment,nitric oxide was higher than before treatment,and the endothelin of the combined treatment group was lower than that of the Metformin group,nitric oxide was higher than that of the Metformin group,the differences were statistically significant(P<0.05).The incidence of adverse prognosis in the combined treatment group was 1.67%,which was lower than 15.00%in the Metformin group,the difference was statistically significant(P<0.05).Conclusion:Metformin combined with Atorvastatin Calcium are effective in T2DM patients with fatty liver,and can effectively improve glucose and lipid metabolism and vascular endothelial function,and have good security.